The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

WANdisco, soon to be Cirata, reports wider loss in "traumatic time"

Mon, 11th Sep 2023 11:36

(Alliance News) - WANdisco PLC on Monday confirmed a near halving in revenue in the first half of 2023, leading to a wider loss, as the company soon to be renamed Cirata PLC faced a "traumatic time" amid the discovery of illegitimate purchase orders.

Shares in the Sheffield, England-based data analysis platform were down 5.9% to 62.29 pence on Monday morning in London. Trading in the stock had been suspended from March until late July after its disclosure of overstated revenue. The price is down 85% over the past 12 months.

As part of its effort to move on, WANdisco will change its name to Cirata by early October. This was approved by shareholders at the end of last month and is meant to provide "a new and positive canvas where the company can build positive brand equity going forward".

On Monday, WANdisco said its pretax loss widened to USD22.5 million in the six months that ended June 30 from USD7.0 million a year before. Revenue dropped to USD3.0 million from USD5.8 million, and the company swung from net finance income of USD10.2 million to cost of USD3.8 million.

Adjusted loss before interest, tax, depreciation and amortisation was USD14.8 million, steady from USD14.1 million a year before.

Looking ahead, WANdisco said it has bookings of USD2.8 million, down from USD7.3 million a year before. In the second half, it expects bookings of USD4.3 million to USD6.0 million, up by between 5% and 46% from a year before. For all of 2023, bookers are expected to be between USD7.1 million and USD8.8 million.

Following the discovery in March of "significant, sophisticated and potentially fraudulent irregularities" involving one senior sales employee, WANdisco said its sales pipeline has been "cleansed and qualified" and what remains is "robust and of high quality".

But it admitted that the scandal was a "traumatic time for shareholders and employees" and had a "significant impact" on prospective customers and partners. Therefore, its sales pipeline is in the "early stages of a rebuild".

"Sadly, very little from the past deserves preservation, except for the excellence of the technology, strong engineering, marquee customers and loyal committed colleagues," said Chief Executive Officer Stephan Kelly, who was brought into WANdisco in May.

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
4 Oct 2023 08:55

Wandisco files paperwork for Cirata rebrand

(Sharecast News) - Technology developer Wandisco confirmed on Wednesday that it has now filed all paperwork related to its rebrand as Cirata.

11 Sep 2023 08:23

WANdisco hopes rebrand will change fortunes after a "traumatic" first half

(Sharecast News) - Shares in WANdisco dropped on Monday morning after the struggling data activation platform confirmed first-half bookings had slumpe...

30 Aug 2023 18:36

IN BRIEF: WANDisco shareholders approve name change to Cirata

WANdisco PLC - Sheffield, England-based data migration platform - Reports all resolutions at annual general meeting were passed. The passing of resolu...

23 Aug 2023 15:42

UK shareholder meetings calendar - next 7 days

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.